Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Douglas Pharmaceuticals Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner, ARNOLD, ERNST V, in 1 distinct art unit. ARNOLD, ERNST V is the busiest examiner for the company, with 1 busiest examiner pending action. This single pending office action represents the entirety of the company's current prosecution activity. The presence of 1 distinct examiner for 1 pending office action indicates that the company's current prosecution is focused on a single case.
Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution strategy is entirely dependent on the interactions with ARNOLD, ERNST V. The busiest examiner pending count of 1 confirms that no other examiners are currently reviewing work for Douglas Pharmaceuticals Ltd. This concentration simplifies the management of the portfolio, as there are no competing examiner perspectives to reconcile. Practitioners should prioritize understanding the specific preferences of ARNOLD, ERNST V within the context of the 1 art unit involved. The 1 pending office action serves as the sole focus of the company's current patent efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850266 | Improved Thiopurine Formulation and Treatment Methods | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18850266 | Improved Thiopurine Formulation and Treatment Methods | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850266 | Improved Thiopurine Formulation and Treatment Methods | ARNOLD, ERNST V | 1613 | §102§103 | Final Rejection | — | Pending | Sep 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDouglas Pharmaceuticals Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Douglas Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
